Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics

Like
Comment
Favorite

Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics

Zacks04-25

In its upcoming report, Eli Lilly (LLY) is predicted by Wall Street analysts to post quarterly earnings of $2.53 per share, reflecting an increase of 56.2% compared to the same period last year. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2430287138?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wbCMwMtKIoXj_iQA0ego4g--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295","is_english":true,"pubTime":"2024-04-25 21:15","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2430287138","market":"us","top_or_hot":-1,"title":"Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics","media":"Zacks","content":"<div>\n<p>In its upcoming report, Eli Lilly (LLY) is predicted by Wall Street analysts to post quarterly earnings of $2.53 per share, reflecting an increase of 56.2% compared to the same period last year. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gear-lilly-lly-q1-earnings-131526700.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-25 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gear-lilly-lly-q1-earnings-131526700.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In its upcoming report, Eli Lilly (LLY) is predicted by Wall Street analysts to post quarterly earnings of $2.53 per share, reflecting an increase of 56.2% compared to the same period last year. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gear-lilly-lly-q1-earnings-131526700.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"https://finance.yahoo.com/news/gear-lilly-lly-q1-earnings-131526700.html","article_id":"2430287138","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wbCMwMtKIoXj_iQA0ego4g--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2430287138","pubTimestamp":1714050926,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"In its upcoming report, Eli Lilly  is predicted by Wall Street analysts to post quarterly earnings of $2.53 per share, reflecting an increase of 56.2% compared to the same period last year. Revenues are forecasted to be $8.81 billion, representing a year-over-year increase of 26.6%.The consensus EPS estimate for the quarter has been revised 0.4% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.Analysts forecast 'Net Sales- Cyramza - Total' to reach $234.66 million. The estimate indicates a year-over","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"为礼来第一季度盈利做好准备：华尔街对关键指标的估计","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"In its upcoming report, Eli Lilly (LLY) is predicted by Wall Street analysts to post quarterly earnings of $2.53 per share, reflecting an increase of 56.2% compared to the same period last year. Revenues are forecasted to be $8.81 billion, representing a year-over-year increase of 26.6%.\nThe consensus EPS estimate for the quarter has been revised 0.4% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.\nBefore a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.\nWhile investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.\nGiven this perspective, it's time to examine the average forecasts of specific Lilly metrics that are routinely monitored and predicted by Wall Street analysts.\nAnalysts forecast 'Net Sales- Cyramza (Ramucirumab /IMC-1121B)- Total' to reach $234.66 million. The estimate indicates a year-over-year change of -0.9%.\nThe consensus among analysts is that 'Net Sales- Humulin [$M]' will reach $207.27 million. The estimate indicates a change of -17.8% from the prior-year quarter.\nAnalysts predict that the 'Net Sales- Humalog [$M]' will reach $390.31 million. The estimate suggests a change of -15.3% year over year.\nIt is projected by analysts that the 'Net Sales- Forteo [$M]' will reach $105.88 million. The estimate indicates a year-over-year change of -13.4%.\nThe combined assessment of analysts suggests that 'Net Sales- Cyramza (Ramucirumab /IMC-1121B) - US' will likely reach $104.81 million. The estimate indicates a change of +4.2% from the prior-year quarter.\nThe consensus estimate for 'Net Sales- International-Humalog [$M]' stands at $180.28 million. The estimate suggests a change of -4.8% year over year.\nAnalysts expect 'Net Sales- International-Forteo [$M]' to come in at $41.14 million. The estimate points to a change of -20.4% from the year-ago quarter.\nThe collective assessment of analysts points to an estimated 'Net Sales- International-Alimta [$M]' of $22.60 million. The estimate indicates a change of -40.7% from the prior-year quarter.\nAnalysts' assessment points toward 'Net Sales- US-Humulin [$M]' reaching $157.99 million. The estimate indicates a change of -20.5% from the prior-year quarter.\nThe average prediction of analysts places 'Net Sales- US-Humalog [$M]' at $210.03 million. The estimate points to a change of -22.7% from the year-ago quarter.\nAccording to the collective judgment of analysts, 'Net Sales- US-Forteo [$M]' should come in at $64.74 million. The estimate indicates a change of -8.4% from the prior-year quarter.\nBased on the collective assessment of analysts, 'Net Sales- US-Alimta [$M]' should arrive at $9.76 million. The estimate suggests a change of -51.4% year over year.View all Key Company Metrics for Lilly here>>>Lilly shares have witnessed a change of -5.9% in the past month, in contrast to the Zacks S&P 500 composite's -3% move. With a Zacks Rank #3 (Hold), LLY is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}